NASDAQ:GNOM Global X Genomics & Biotechnology ETF (GNOM) Price, Holdings, & News $54.17 0.00 (0.00%) As of 07/31/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsTrendsBuy This Stock About Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get GNOM alerts:Sign Up Key Stats Today's Range$53.75▼$55.2850-Day Range$46.54▼$58.8352-Week Range$34.04▼$59.48Volume7,242 shsAverage Volume15,378 shsMarket Capitalization$79.09 millionAssets Under Management$79.65 millionDividend YieldN/ANet Expense Ratio0.50%Aggregate RatingModerate Buy ETF Overview Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company. Read More Global X Genomics & Biotechnology ETF ExpensesTypeGNOMTheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.50%0.57%0.57%0.54%0.53%Other Expenses0.00%0.57%0.53%0.39%0.54%Total Expense0.50%0.72%0.75%0.69%0.73%Fee Waiver0.00%-0.72%-0.67%-0.41%-0.68%Net Expense0.50%0.60%0.63%0.61%0.60% Receive GNOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global X Genomics & Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GNOM ETF News HeadlinesGlobal X Genomics & Biotechnology ETFJuly 31 at 5:01 PM | markets.businessinsider.comETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins?July 21, 2026 | 247wallst.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.August 3 at 1:00 AM | Weiss Ratings (Ad)Genomics & biotechnology ETF declares semi-annual distribution of $0.057900June 29, 2026 | msn.comGlobal X Genomics & Biotechnology ETF declares semi-annual distribution of $0.0083June 30, 2025 | msn.com10x Genomics Misses Revenue ForecastOctober 29, 2024 | fool.comSee More Headlines GNOM ETF - Frequently Asked Questions How have GNOM shares performed this year? Global X Genomics & Biotechnology ETF's stock was trading at $45.46 at the start of the year. Since then, GNOM stock has increased by 19.2% and is now trading at $54.17. When did Global X Genomics & Biotechnology ETF's stock split? Global X Genomics & Biotechnology ETF shares reverse split before market open on Tuesday, September 2nd 2025.A 1-4 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 1st 2025. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. How do I buy shares of Global X Genomics & Biotechnology ETF? Shares of GNOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Global X Genomics & Biotechnology ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Global X Genomics & Biotechnology ETF investors own include Meta Platforms (META), NVIDIA (NVDA), Teladoc Health (TDOC), Intel (INTC), Alibaba Group (BABA) and PayPal (PYPL). Fund Details IssuerGlobal X Fund NameGlobal X Genomics & Biotechnology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:GNOM Inception Date4/5/2019 Fund ManagerChang Kim, James Ong, Nam To, Wayne Xie Webwww.completegenomics.com Phone+1-650-9432800Fund Focus Asset ClassEquity BenchmarkSolactive Genomics Index CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings52 Fund Statistics Assets Under Management$79.65 million Average Daily Volume$0.00 Discount/Premium-0.21% Administrator, Advisor and Custodian AdministratorGlobal X Management Company LLC AdvisorGlobal X Management Company LLC CustodianBrown Brothers Harriman & Co. DistributorSEI Investments Distribution Co. Transfer AgentBrown Brothers Harriman & Co. TrusteeN/A Lead Market MakerSusquehanna Miscellaneous Outstanding Shares1,460,000Beta1.16 Creation Unit50,000 Creation Fee$500.00 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report Top 10 GNOM HoldingsGuardant Health (NASDAQ:GH)Holding Weight: 6.38%Illumina (NASDAQ:ILMN)Holding Weight: 5.54%Twist Bioscience (NASDAQ:TWST)Holding Weight: 4.96%10x Genomics (NASDAQ:TXG)Holding Weight: 4.92%Natera (NASDAQ:NTRA)Holding Weight: 4.54%Bio-Techne (NASDAQ:TECH)Holding Weight: 4.34%Arrowhead Pharmaceuticals (NASDAQ:ARWR)Holding Weight: 4.04%BioMarin Pharmaceutical (NASDAQ:BMRN)Holding Weight: 3.91%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 3.84%Qiagen (NYSE:QGEN)Holding Weight: 3.65%Full Holdings DetailsGNOM Sector ExposureGNOM Industry Exposure This page (NASDAQ:GNOM) was last updated on 8/3/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global X Genomics & Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Global X Genomics & Biotechnology ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
